Different patterns of longitudinal changes in antinuclear antibodies titers in children with systemic lupus erythematosus and Sjögren's syndrome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: England NLM ID: 9204265 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0962 (Electronic) Linking ISSN: 09612033 NLM ISO Abbreviation: Lupus Subsets: MEDLINE
    • Publication Information:
      Publication: London : SAGE Publications
      Original Publication: Houndmills, Basingstoke, Hampshire, UK : Scientific & Medical Division, Macmillan Press Ltd., c1991-
    • Subject Terms:
      Sjogren's Syndrome*/immunology ; Sjogren's Syndrome*/blood ; Antibodies, Antinuclear*/blood ; Antibodies, Antinuclear*/immunology ; Lupus Erythematosus, Systemic*/immunology ; Lupus Erythematosus, Systemic*/blood; Humans ; Female ; Child ; Male ; Adolescent ; Longitudinal Studies ; Child, Preschool ; Follow-Up Studies
    • Abstract:
      Objective: to investigate the trend of autoantibody titers during a 2-year follow-up in pediatric systemic lupus erythematosus (pSLE) and pediatric Sjögren's syndrome (pSS).
      Methods: Autoantibodies testing was performed every 3-4 months during 2 years from disease onset in a cohort of children with pSLE and pSS.
      Results: We enrolled 21 children with pSLE and 22 children with pSS. All pSLE patients at 2 years showed ANA titers significantly lower compared to disease onset. Eleven patients (73%) were still ANA positive at 2 years, while 4 (26%) became ANA negative. At diagnosis, 12 (80%) patients showed a homogeneous pattern, while 3 (20%) patients showed a speckled pattern. The latter remained ANA positive with the same pattern; only 2 patients with a homogenous pattern converted to speckled, 4 patients with a homogeneous pattern became ANA negative. ANA negative pSLE patients showed lower levels of interferon score compared to ANA positive patients. Anti-dsDNA titers declined equally in the two groups. All patients with pSS, at disease onset, were ANA and anti-Ro positive and 14 (66%) were anti-La positive. After 2 years of follow-up, 100% remained ANA positive but showed significant lower titers. During follow-up anti-Ro and anti-La titers remained stable.
      Conclusion: different patterns in changes of ANA and ENA titers in pSLE and pSS were shown. At 2 years of follow-up, all pSLE patients had a lower ANA titer and 26% became negative; however, all pSS patients remained both ANA and ENA positive. This evidence may be due to different pathogenetic pathways in SLE and pSS.
      Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
    • References:
      Ann Rheum Dis. 2016 Nov;75(11):2014-2021. (PMID: 27088255)
      Front Immunol. 2015 Aug 20;6:412. (PMID: 26347739)
      J Exp Med. 2005 Mar 7;201(5):703-11. (PMID: 15738055)
      Science. 2003 Sep 5;301(5638):1374-7. (PMID: 12920303)
      Clin Exp Rheumatol. 1999 May-Jun;17(3):381-6. (PMID: 10410277)
      Eur J Immunol. 2023 Jul;53(7):e2250319. (PMID: 37204055)
      Scand J Rheumatol. 2000;29(2):116-23. (PMID: 10777125)
      J Rheumatol. 2005 Jul;32(7):1267-72. (PMID: 15996063)
      Clin Exp Rheumatol. 2013 Jul-Aug;31(4):656. (PMID: 23582543)
      Ann Rheum Dis. 2019 Sep;78(9):1151-1159. (PMID: 31383717)
      N Engl J Med. 2001 Aug 2;345(5):340-50. (PMID: 11484692)
      Ann Rheum Dis. 2022 Aug;81(8):1143-1150. (PMID: 35338033)
      Clin Exp Rheumatol. 1999 Jan-Feb;17(1):63-8. (PMID: 10084034)
      J Rheumatol. 2008 Oct;35(10):1994-2000. (PMID: 18785312)
      J Appl Lab Med. 2022 Jan 5;7(1):26-35. (PMID: 34996068)
      Arthritis Rheum. 2009 Sep 15;61(9):1168-78. (PMID: 19714604)
      J Autoimmun. 1998 Feb;11(1):29-38. (PMID: 9480721)
      Clin Exp Immunol. 2020 Mar;199(3):245-254. (PMID: 31778219)
      Nat Immunol. 2015 Jul;16(7):755-65. (PMID: 26006014)
      Rheumatology (Oxford). 2021 Jul 1;60(7):3144-3155. (PMID: 33280020)
      J Allergy Clin Immunol. 2019 Apr;143(4):1586-1597. (PMID: 30439406)
      RMD Open. 2024 Mar 6;10(1):. (PMID: 38453214)
      N Engl J Med. 2003 Oct 16;349(16):1526-33. (PMID: 14561795)
      Immunol Rev. 2019 Nov;292(1):61-75. (PMID: 31556969)
      Arthritis Rheum. 1981 Oct;24(10):1236-44. (PMID: 6975630)
      Arthritis Rheum. 2003 May;48(5):1332-42. (PMID: 12746906)
      Arthritis Rheumatol. 2016 Sep;68(9):2210-20. (PMID: 27059652)
      Clin Immunol Immunopathol. 1990 Feb;54(2):266-80. (PMID: 2104788)
      Lancet Neurol. 2013 Dec;12(12):1159-69. (PMID: 24183309)
    • Contributed Indexing:
      Keywords: Antinuclear antibodies (ANA); extractable nuclear antigen (ENA); interferon (IFN) signature; sjögren’s syndrome (SS); systemic lupus erythematosus (SLE)
    • Accession Number:
      0 (Antibodies, Antinuclear)
      0 (SS-A antibodies)
    • Publication Date:
      Date Created: 20241104 Date Completed: 20241203 Latest Revision: 20241205
    • Publication Date:
      20241209
    • Accession Number:
      PMC11613521
    • Accession Number:
      10.1177/09612033241298729
    • Accession Number:
      39494571